FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892062705> ?p ?o ?g. }

• W2892062705 endingPage "4007" @default.
• W2892062705 startingPage "4007" @default.
• W2892062705 abstract "4007 Background: Although postoperative adjuvant chemotherapy with S-1 is among the standard treatments for curatively resected pStage II/III gastric cancer (GC) in Asia, the outcome of pStage III GC remains unsatisfactory. Postoperative S-1/docetaxel had been among candidates for the new standard treatment. Methods: JACCRO GC-7, a randomized controlled trial to explore postoperative S-1/docetaxel, was participated by 138 Japanese institutions. After R0 resection by D2 gastrectomy, patients with pStage III GC were randomly assigned to either the S-1/docetaxel group (oral S-1 at 80-120mg/body on days 1-14 with 7 days of rest was followed by 6 cycles of S-1 at the same dosage and schedule combined with docetaxel 40mg/m2 on day 1 of each cycle, and then 4 further cycles of S-1 at 80-120mg/body on days 1-28 every 42 days) or the control group (8 cycles of S-1 at 80-120mg/body on days 1-28 every 42 days). Block randomization was performed by a central interactive computerized system stratified by the institution, stage (IIIA, IIIB, or IIIC) and histological type (differentiated or undifferentiated). The sample size of 1,100 was necessary to detect a 7% increase in the 3-year RFS, the primary endpoint, in the S-1/docetaxel group (HR 0.78, 2-sided alpha = 0.05, beta = 0.2). The secondary endpoints were OS, TTF and safety. Results: At the planned second interim analysis, the 3y RFS of the S-1/docetaxel arm (65.9%) was significantly superior to that of the S-1 arm at 49,6% (HR 0.632, 99% CI: 0.400~0.998, p = 0.0007), and the independent data and safety monitoring committee recommended termination of the trial. S-1/docetaxel suppressed all types of recurrences including hematogenous, lymphatic and peritoneal. Although ≥grade 3 adverse events including leucopenia, anorexia, stomatitis and anemia were more frequent, postoperative S-1/docetaxel was safe and manageable. Conclusions: Postoperative adjuvant S-1/docetaxel after D2 gastrectomy is recommended as the new standard of care for patients with pStage III GC. Clinical trial information: UMIN 000010337." @default.
• W2892062705 created "2018-09-27" @default.
• W2892062705 creator A5003529696 @default.
• W2892062705 creator A5008014743 @default.
• W2892062705 creator A5011507410 @default.
• W2892062705 creator A5018087364 @default.
• W2892062705 creator A5018146056 @default.
• W2892062705 creator A5024742184 @default.
• W2892062705 creator A5027482562 @default.
• W2892062705 creator A5029308720 @default.
• W2892062705 creator A5034040686 @default.
• W2892062705 creator A5040552693 @default.
• W2892062705 creator A5046358579 @default.
• W2892062705 creator A5053884946 @default.
• W2892062705 creator A5064137979 @default.
• W2892062705 creator A5065994095 @default.
• W2892062705 creator A5074557622 @default.
• W2892062705 creator A5076136934 @default.
• W2892062705 creator A5076533221 @default.
• W2892062705 creator A5078062326 @default.
• W2892062705 creator A5087398756 @default.
• W2892062705 creator A5091166755 @default.
• W2892062705 date "2018-05-20" @default.
• W2892062705 modified "2023-10-06" @default.
• W2892062705 title "A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial)." @default.
• W2892062705 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.4007" @default.
• W2892062705 hasPublicationYear "2018" @default.
• W2892062705 type Work @default.
• W2892062705 sameAs 2892062705 @default.
• W2892062705 citedByCount "21" @default.
• W2892062705 countsByYear W28920627052018 @default.
• W2892062705 countsByYear W28920627052019 @default.
• W2892062705 countsByYear W28920627052020 @default.
• W2892062705 countsByYear W28920627052021 @default.
• W2892062705 countsByYear W28920627052023 @default.
• W2892062705 crossrefType "journal-article" @default.
• W2892062705 hasAuthorship W2892062705A5003529696 @default.
• W2892062705 hasAuthorship W2892062705A5008014743 @default.
• W2892062705 hasAuthorship W2892062705A5011507410 @default.
• W2892062705 hasAuthorship W2892062705A5018087364 @default.
• W2892062705 hasAuthorship W2892062705A5018146056 @default.
• W2892062705 hasAuthorship W2892062705A5024742184 @default.
• W2892062705 hasAuthorship W2892062705A5027482562 @default.
• W2892062705 hasAuthorship W2892062705A5029308720 @default.
• W2892062705 hasAuthorship W2892062705A5034040686 @default.
• W2892062705 hasAuthorship W2892062705A5040552693 @default.
• W2892062705 hasAuthorship W2892062705A5046358579 @default.
• W2892062705 hasAuthorship W2892062705A5053884946 @default.
• W2892062705 hasAuthorship W2892062705A5064137979 @default.
• W2892062705 hasAuthorship W2892062705A5065994095 @default.
• W2892062705 hasAuthorship W2892062705A5074557622 @default.
• W2892062705 hasAuthorship W2892062705A5076136934 @default.
• W2892062705 hasAuthorship W2892062705A5076533221 @default.
• W2892062705 hasAuthorship W2892062705A5078062326 @default.
• W2892062705 hasAuthorship W2892062705A5087398756 @default.
• W2892062705 hasAuthorship W2892062705A5091166755 @default.
• W2892062705 hasConcept C121608353 @default.
• W2892062705 hasConcept C126322002 @default.
• W2892062705 hasConcept C141071460 @default.
• W2892062705 hasConcept C168563851 @default.
• W2892062705 hasConcept C203092338 @default.
• W2892062705 hasConcept C2776694085 @default.
• W2892062705 hasConcept C2780470880 @default.
• W2892062705 hasConcept C2781190966 @default.
• W2892062705 hasConcept C61943457 @default.
• W2892062705 hasConcept C71924100 @default.
• W2892062705 hasConcept C90924648 @default.
• W2892062705 hasConceptScore W2892062705C121608353 @default.
• W2892062705 hasConceptScore W2892062705C126322002 @default.
• W2892062705 hasConceptScore W2892062705C141071460 @default.
• W2892062705 hasConceptScore W2892062705C168563851 @default.
• W2892062705 hasConceptScore W2892062705C203092338 @default.
• W2892062705 hasConceptScore W2892062705C2776694085 @default.
• W2892062705 hasConceptScore W2892062705C2780470880 @default.
• W2892062705 hasConceptScore W2892062705C2781190966 @default.
• W2892062705 hasConceptScore W2892062705C61943457 @default.
• W2892062705 hasConceptScore W2892062705C71924100 @default.
• W2892062705 hasConceptScore W2892062705C90924648 @default.
• W2892062705 hasIssue "15_suppl" @default.
• W2892062705 hasLocation W28920627051 @default.
• W2892062705 hasOpenAccess W2892062705 @default.
• W2892062705 hasPrimaryLocation W28920627051 @default.
• W2892062705 hasRelatedWork W2085307618 @default.
• W2892062705 hasRelatedWork W2114983792 @default.
• W2892062705 hasRelatedWork W2412448412 @default.
• W2892062705 hasRelatedWork W2415186990 @default.
• W2892062705 hasRelatedWork W2417822374 @default.
• W2892062705 hasRelatedWork W3082225243 @default.
• W2892062705 hasRelatedWork W3135647258 @default.
• W2892062705 hasRelatedWork W4230237492 @default.
• W2892062705 hasRelatedWork W4298008142 @default.
• W2892062705 hasRelatedWork W4324136309 @default.
• W2892062705 hasVolume "36" @default.
• W2892062705 isParatext "false" @default.
• W2892062705 isRetracted "false" @default.
• W2892062705 magId "2892062705" @default.
• W2892062705 workType "article" @default.